vs
Side-by-side financial comparison of NATIONAL BANKSHARES INC (NKSH) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
NATIONAL BANKSHARES INC is the larger business by last-quarter revenue ($15.3M vs $9.1M, roughly 1.7× Protalix BioTherapeutics, Inc.). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs -60.3%, a 98.8% gap on every dollar of revenue. On growth, NATIONAL BANKSHARES INC posted the faster year-over-year revenue change (24.7% vs -49.9%). NATIONAL BANKSHARES INC produced more free cash flow last quarter ($15.2M vs $1.6M). Over the past eight quarters, NATIONAL BANKSHARES INC's revenue compounded faster (20.9% CAGR vs -6.7%).
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
NKSH vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.3M | $9.1M |
| Net Profit | $5.9M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 47.4% | -51.1% |
| Net Margin | 38.5% | -60.3% |
| Revenue YoY | 24.7% | -49.9% |
| Net Profit YoY | 91.0% | -184.8% |
| EPS (diluted) | $0.93 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.3M | $9.1M | ||
| Q3 25 | $14.2M | $17.9M | ||
| Q2 25 | $13.3M | $15.7M | ||
| Q1 25 | $12.8M | $10.1M | ||
| Q4 24 | $12.2M | $18.2M | ||
| Q3 24 | $11.7M | $18.0M | ||
| Q2 24 | $10.9M | $13.5M | ||
| Q1 24 | $10.4M | — |
| Q4 25 | $5.9M | $-5.5M | ||
| Q3 25 | $4.4M | $2.4M | ||
| Q2 25 | $2.3M | $164.0K | ||
| Q1 25 | $3.2M | $-3.6M | ||
| Q4 24 | $3.1M | $6.5M | ||
| Q3 24 | $2.7M | $3.2M | ||
| Q2 24 | $-307.0K | $-2.2M | ||
| Q1 24 | $2.2M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 47.4% | -51.1% | ||
| Q3 25 | 37.9% | 11.9% | ||
| Q2 25 | 20.0% | 7.5% | ||
| Q1 25 | 30.5% | -41.0% | ||
| Q4 24 | 30.1% | 39.6% | ||
| Q3 24 | 27.5% | 22.2% | ||
| Q2 24 | -4.4% | -18.0% | ||
| Q1 24 | 25.8% | — |
| Q4 25 | 38.5% | -60.3% | ||
| Q3 25 | 31.1% | 13.2% | ||
| Q2 25 | 17.2% | 1.0% | ||
| Q1 25 | 25.3% | -35.8% | ||
| Q4 24 | 25.1% | 35.6% | ||
| Q3 24 | 22.8% | 18.0% | ||
| Q2 24 | -2.8% | -16.4% | ||
| Q1 24 | 20.8% | — |
| Q4 25 | $0.93 | $-0.06 | ||
| Q3 25 | $0.69 | $0.03 | ||
| Q2 25 | $0.36 | $0.00 | ||
| Q1 25 | $0.51 | $-0.05 | ||
| Q4 24 | $0.50 | $0.10 | ||
| Q3 24 | $0.42 | $0.03 | ||
| Q2 24 | $-0.05 | $-0.03 | ||
| Q1 24 | $0.37 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $59.3M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $184.9M | $48.2M |
| Total Assets | $1.8B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $59.3M | $14.7M | ||
| Q3 25 | $42.3M | $13.6M | ||
| Q2 25 | $92.8M | $17.9M | ||
| Q1 25 | $122.5M | $19.5M | ||
| Q4 24 | $108.1M | $19.8M | ||
| Q3 24 | $49.8M | $27.4M | ||
| Q2 24 | $98.9M | $23.4M | ||
| Q1 24 | $121.2M | — |
| Q4 25 | $184.9M | $48.2M | ||
| Q3 25 | $179.2M | $52.9M | ||
| Q2 25 | $168.7M | $49.9M | ||
| Q1 25 | $167.3M | $45.2M | ||
| Q4 24 | $156.4M | $43.2M | ||
| Q3 24 | $167.8M | $32.4M | ||
| Q2 24 | $149.0M | $28.6M | ||
| Q1 24 | $139.4M | — |
| Q4 25 | $1.8B | $82.3M | ||
| Q3 25 | $1.8B | $82.3M | ||
| Q2 25 | $1.8B | $78.5M | ||
| Q1 25 | $1.8B | $73.9M | ||
| Q4 24 | $1.8B | $73.4M | ||
| Q3 24 | $1.8B | $61.6M | ||
| Q2 24 | $1.8B | $91.5M | ||
| Q1 24 | $1.7B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.9M | $2.0M |
| Free Cash FlowOCF − Capex | $15.2M | $1.6M |
| FCF MarginFCF / Revenue | 99.2% | 17.8% |
| Capex IntensityCapex / Revenue | 17.9% | 4.4% |
| Cash ConversionOCF / Net Profit | 3.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | $23.6M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.9M | $2.0M | ||
| Q3 25 | $6.1M | $-3.7M | ||
| Q2 25 | $2.1M | $-5.2M | ||
| Q1 25 | $2.6M | $-5.1M | ||
| Q4 24 | $9.4M | $4.0M | ||
| Q3 24 | $3.1M | $4.1M | ||
| Q2 24 | $-3.0M | $-3.6M | ||
| Q1 24 | $3.8M | — |
| Q4 25 | $15.2M | $1.6M | ||
| Q3 25 | $5.3M | $-4.2M | ||
| Q2 25 | $1.5M | $-5.7M | ||
| Q1 25 | $1.6M | $-5.4M | ||
| Q4 24 | $6.2M | $3.6M | ||
| Q3 24 | $2.2M | $4.0M | ||
| Q2 24 | $-4.0M | $-3.8M | ||
| Q1 24 | $3.5M | — |
| Q4 25 | 99.2% | 17.8% | ||
| Q3 25 | 37.4% | -23.7% | ||
| Q2 25 | 11.5% | -36.2% | ||
| Q1 25 | 12.5% | -53.0% | ||
| Q4 24 | 50.5% | 19.6% | ||
| Q3 24 | 18.5% | 22.4% | ||
| Q2 24 | -36.3% | -28.1% | ||
| Q1 24 | 33.8% | — |
| Q4 25 | 17.9% | 4.4% | ||
| Q3 25 | 5.6% | 2.8% | ||
| Q2 25 | 4.1% | 2.8% | ||
| Q1 25 | 7.5% | 3.0% | ||
| Q4 24 | 26.6% | 2.3% | ||
| Q3 24 | 8.3% | 0.5% | ||
| Q2 24 | 9.3% | 1.3% | ||
| Q1 24 | 3.0% | — |
| Q4 25 | 3.04× | — | ||
| Q3 25 | 1.38× | -1.58× | ||
| Q2 25 | 0.90× | -31.91× | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 3.07× | 0.61× | ||
| Q3 24 | 1.17× | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.77× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NKSH
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
